Bio-Risk - Line of Research


We analyze trends to help government and society harness biotechnology’s potential to promote health and new industries, as well as understand the potential for its misuse. It includes examination of the biotechnology workforce, infrastructure and funding that supports biotechnology research. Research topics include biological safety infrastructure and regulations, global biosecurity policies, genome editing techniques and the use of AI in biological discovery.

Recent Publications


China and Medical AI

Caroline Schuerger Vikram Venkatram Katherine Quinn
| May 2024

Medical artificial intelligence, which depends on large repositories of biological data, can improve public health and contribute to the growing global bioeconomy. Countries that strategically prioritize medical AI could benefit from a competitive advantage and set global norms. This report examines China’s stated goals for medical AI, finding that the...

Read More


China, Biotechnology, and BGI

Anna Puglisi Chryssa Rask
| May 2024

As the U.S. government considers banning genomics companies from China, it opens a broader question about how the United States and other market economies should deal with China’s “national champions.” This paper provides an overview of one such company—BGI—and how China’s industrial policy impacts technology development in China and around...

Read More


AI and Biorisk: An Explainer

Steph Batalis
| December 2023

Recent government directives, international conferences, and media headlines reflect growing concern that artificial intelligence could exacerbate biological threats. When it comes to biorisk, AI tools are cited as enablers that lower information barriers, enhance novel biothreat design, or otherwise increase a malicious actor’s capabilities. In this explainer, CSET Biorisk Research...

Read More

Recent Blog Articles

China’s Hybrid Economy: What to Do about BGI?

Anna Puglisi
| February 2, 2024

As the U.S. government considers banning genomics companies from China in the Biosecure Act, it opens a broader question of how the U.S. and other market economies should deal with China’s national champions. This blog post provides an overview of BGI and how China’s industrial policy impacts technology development.

Read More

CSET’s Must Read Research: A Primer

Tessa Baker
| December 18, 2023

This guide provides a run-down of CSET’s research since 2019 for first-time visitors and long-term fans alike. Quickly get up to speed on our “must-read” research and learn about how we organize our work.

Read More

Breaking Down the Biden AI EO: Screening DNA Synthesis and Biorisk

Steph Batalis Vikram Venkatram
| November 16, 2023

The recent Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence will have major implications for biotechnology. The EO demonstrates that the White House considers biorisk a major concern for AI safety and security. In this blog post CSET’s bio experts...

Read More

Our People

Katherine Quinn

Data Scientist

Steph Batalis

Research Fellow

Vikram Venkatram

Research Analyst

Related News

In a Washington Post article that delves into China's extensive efforts to collect genetic data from around the world, using innovative technology, CSET's Anna Puglisi provided her expert insights.
CSET's Anna Puglisi was featured in a Nature article along with a report she co-authored. The article discusses the challenges faced by US policymakers in regulating research involving potentially harmful pathogens. The focal point of the discussion is the CSET report titled “Understanding the Global Gain-of-Function Research Landscape.”
CSET Director of Biotechnology Programs and Senior Fellow Anna Puglisi provided insights into China's illicit efforts to acquire genetic data from the United States in Politico's Morning Cybersecurity. She pointed out that such data will serve a wide variety of interests, from health care to agriculture. “It’s enablers like sequencing and other tools of discovery that are going to drive the bioeconomy, that are going to drive precision medicine,” she said. “The more data you have, the more you can start to understand what genes do.”